Precision-MRD: Targeted therapy study for colorectal cancer with MRD
Part of Cancer, Digestive system clinical trials.
This study looks at how well targeted therapies work for people with colorectal cancer who have minimal residual disease (MRD, tiny amounts of cancer left after treatment) detected by a blood test. It is for people who have a specific genetic change (biomarker) in their tumor and have not been treated with the targeted therapy for that biomarker before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with colorectal cancer that has spread to nearby tissues or further (stage 2-4), but there is no clear sign of cancer on imaging after treatment.
- You have one of these genetic changes in your tumor: BRAF V600E, KRAS G12C, MSI-H (a type of DNA repair problem), or HER2 amplification.
- You have a positive ctDNA blood test (a test that finds tiny cancer DNA in your blood) taken at least 21 days after surgery or after finishing your last adjuvant therapy (chemo after surgery).
- You have not already received treatment with the targeted therapy for your specific genetic change (like BRAF inhibitors, KRAS G12C inhibitors, immunotherapy for MSI-H, or HER2 therapies).
- You do not have another cancer that needs active treatment right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different chemotherapy combinations given after surgery to prevent cancer from coming back in people with colorectal cancer who have minimal residual disease (MRD), meaning there are still tiny traces of cancer DNA in the blood. A more intense regimen may work better for this group, and the trial checks if it is safe and more effective.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests if combining three targeted drugs (cetuximab, encorafenib, and binimetinib) before surgery can shrink or control cancer in people with a specific BRAF V600E mutation and a stable (MSS) tumor. It focuses on colorectal cancer that is either already able to be removed or could become removable with treatment.
This trial tests a combination of targeted drugs for people with advanced colorectal cancer that has not responded to prior treatment. The drugs aim to block cancer growth by targeting specific gene changes and may boost the immune system to fight the cancer.
This trial checks “MRD” (tiny leftover cancer signals after surgery) to help decide the best additional treatment for early-stage breast cancer. It may help tailor therapy so you get the most useful medicines while avoiding unnecessary treatment.
This study looks at using a blood test to find cancer DNA and guide treatment for people with stage IV colorectal cancer that has a specific genetic pattern. The goal is to see if this approach can help monitor the cancer and personalize treatment.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.